Atlas FDA

THERASCREEN EGFR RGQ PCR KIT

FDA premarket approval P120022/S014 · decided 2017-05-19

Approval details

PMA number
P120022
Supplement
S014
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
THERASCREEN EGFR RGQ PCR KIT
Generic name
Somatic gene mutation detection system
Applicant
QIAGEN GmbH
Date received
2016-12-28
Decision date
2017-05-19
Days to decision
142 days
Decision code
APPR
Product code
OWD
Advisory committee
Pathology
Expedited review
No
Location
Hilden
Statement
Approval for changes to the Instructions for Use.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
QIAstat-Dx BCID GPF Plus AMR Panel (K254194)QIAGEN GmbH2026-08-06
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K254032)QIAGEN GmbH2026-03-09
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K252329)QIAGEN GmbH2025-10-22
QIAstat-Dx Respiratory Panel Plus; QIAstat-Dx Respiratory Panel Mini (K250080)QIAGEN GmbH2025-08-27
QIAstat-Dx GI Panel 2 Mini B (K250324)QIAGEN GmbH2025-02-28
QIAstat-Dx GI Panel 2 Mini B&V (K243813)QIAGEN GmbH2025-01-08
QIAstat-Dx Meningitis/Encephalitis (ME) Panel (K242256)QIAGEN GmbH2024-10-29
QIAstat-Dx Respiratory Panel Mini (K242353)QIAGEN GmbH2024-10-25